| pubmed-article:8612316 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8612316 | lifeskim:mentions | umls-concept:C0040690 | lld:lifeskim |
| pubmed-article:8612316 | lifeskim:mentions | umls-concept:C0683598 | lld:lifeskim |
| pubmed-article:8612316 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:8612316 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:8612316 | pubmed:dateCreated | 1996-6-6 | lld:pubmed |
| pubmed-article:8612316 | pubmed:abstractText | The potential role of transforming growth factor-beta in in vivo resistance was examined by administration of transforming growth factor-beta-neutralizing antibodies to animals bearing the EMT-6/Parent tumor or the antitumor alkylating resistance tumors, EMT-6/CTX or EMT-6/CDDP. Treatment of tumor bearing animals with anti-TGF-beta antibodies by intraperitoneal injection daily on days 0-8 post-tumor cell implantation increased the sensitivity of the EMT-6/Parent tumor to cyclophosphamide (CTX) and cisplatin (CDDP) and markedly increased the sensitivity of the EMT-6/CTX tumor to CTX and the EMT6/CDDP tumor to CDDP, as determined by tumor cell survival assay. Bone marrow granulocyte-macrophage colony-forming units (CFU-GM) survival was determined from these same animals. The increase in the sensitivity in the tumors upon treatment with the anti-TGF-beta antibodies was also observed in increased sensitivity of the bone marrow CFU-GM to CTX and CDDP. Treatment of non-tumor-bearing animals with the anti-TGF-beta regimen did not alter blood ATP or serum glucose level but did decrease serum lactate levels. This treatment also decreased hepatic glutathione, glutathione S-transferase, glutathione reductase, and glutathione peroxidase in non-tumor bearing animals by 40-60% but increased hepatic cytochrome P450 reductase in these normal animals. Animals bearing the EMT-6/CTX and EMT-6/CDDP tumors had higher serum lactate levels than normal or EMT-6/Parent tumor-bearing animals; these were decreased by the anti-TGF-beta regimen. Treatment of animals bearing any of the three tumors with the anti-TGF-beta regimen decreased by 30-50% the activity of hepatic glutathione S-transferase and glutathione peroxidase, and increased by 35-80% the activity of hepatic cytochrome P450 reductase. In conclusion, treatment with transforming growth factor-beta-neutralizing antibodies restored drug sensitivity in the alkylating agent-resistant tumors, altering both the tumor and host metabolic states. | lld:pubmed |
| pubmed-article:8612316 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8612316 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8612316 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8612316 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8612316 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8612316 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8612316 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8612316 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8612316 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8612316 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:8612316 | pubmed:author | pubmed-author:ChenGG | lld:pubmed |
| pubmed-article:8612316 | pubmed:author | pubmed-author:TeicherB ABA | lld:pubmed |
| pubmed-article:8612316 | pubmed:author | pubmed-author:ArpHH | lld:pubmed |
| pubmed-article:8612316 | pubmed:author | pubmed-author:HoldenS ASA | lld:pubmed |
| pubmed-article:8612316 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8612316 | pubmed:volume | 37 | lld:pubmed |
| pubmed-article:8612316 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8612316 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8612316 | pubmed:pagination | 601-9 | lld:pubmed |
| pubmed-article:8612316 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8612316 | pubmed:meshHeading | pubmed-meshheading:8612316-... | lld:pubmed |
| pubmed-article:8612316 | pubmed:meshHeading | pubmed-meshheading:8612316-... | lld:pubmed |
| pubmed-article:8612316 | pubmed:meshHeading | pubmed-meshheading:8612316-... | lld:pubmed |
| pubmed-article:8612316 | pubmed:meshHeading | pubmed-meshheading:8612316-... | lld:pubmed |
| pubmed-article:8612316 | pubmed:meshHeading | pubmed-meshheading:8612316-... | lld:pubmed |
| pubmed-article:8612316 | pubmed:meshHeading | pubmed-meshheading:8612316-... | lld:pubmed |
| pubmed-article:8612316 | pubmed:meshHeading | pubmed-meshheading:8612316-... | lld:pubmed |
| pubmed-article:8612316 | pubmed:meshHeading | pubmed-meshheading:8612316-... | lld:pubmed |
| pubmed-article:8612316 | pubmed:meshHeading | pubmed-meshheading:8612316-... | lld:pubmed |
| pubmed-article:8612316 | pubmed:meshHeading | pubmed-meshheading:8612316-... | lld:pubmed |
| pubmed-article:8612316 | pubmed:meshHeading | pubmed-meshheading:8612316-... | lld:pubmed |
| pubmed-article:8612316 | pubmed:meshHeading | pubmed-meshheading:8612316-... | lld:pubmed |
| pubmed-article:8612316 | pubmed:meshHeading | pubmed-meshheading:8612316-... | lld:pubmed |
| pubmed-article:8612316 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8612316 | pubmed:articleTitle | Transforming growth factor-beta in in vivo resistance. | lld:pubmed |
| pubmed-article:8612316 | pubmed:affiliation | Dana-Farber Cancer Institute, Boston, 02115, USA. | lld:pubmed |
| pubmed-article:8612316 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8612316 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8612316 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8612316 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8612316 | lld:pubmed |
